Feeds:
Posts
Comments

Posts Tagged ‘Weizmann Institute of Science’


Prostate Cancer: Diagnosis and Novel Treatment – Articles of Note  @PharmaceuticalIntelligence.com

Curators: Larry H. Bernstein, MD, FCAP, Aviva Lev-Ari, PhD, RN

 

Tookad appears to be more than OK!

 

VIEW VIDEO

 

Weizmann-developed drug may be speedy prostate cancer cure, studies show

In a trial, a photosynthesis-based therapy eliminates cancer in over 80% of patients – and could be used to attack other cancers, too. After 2-year clinical trial, therapy approved for marketing in Mexico; application submitted for Europe.
http://www.timesofisrael.com/weizmann-developed-drug-cures-prostate-cancer-in-90-minutes-studies-show

cancer-cells-541954_1920-635x357

By David Shamah Apr 3, 2016, 5:05 pm

http://cdn.timesofisrael.com/uploads/2016/04/cancer-cells-541954_1920-635×357.jpg

Scientists at the Weizmann Institute may have found the cure for prostate cancer, at least if it is caught in its early stages – via a drug that doctors inject into cancerous cells and treat with infrared laser illumination.

Using a therapy lasting 90 minutes, the drug, called Tookad Soluble, targets and destroys cancerous prostate cells, studies show, allowing patients to check out of the hospital the same day without the debilitating effects of chemical or radiation therapy or the invasive surgery that is usually used to treat this disease.

The drug has been tested in Europe and in several Latin American countries, and is being marketed by Steba Biotech, an Israeli biotech start-up with R&D facilities in Ness Ziona. The drug and its accompanying therapy were developed in the lab of Weizmann Institute professors Yoram Salomon of the Biological Regulation Department and Avigdor Scherz of the Plant and Environmental Sciences Department.

Based on principles of photosynthesis, the drug uses infrared illumination to activate elements that choke off cancer cells, but spares the healthy ones.

The therapy was recently approved for marketing in Mexico, after a two-year Phase III clinical trial in which 80 patients from Mexico, Peru and Panama who suffered from early-stage prostate cancer were treated with the Tookad system. Two years after treatment, over 80% of the study’s subjects remained cancer-free.

A similar study being undertaken in Europe showed similar results, Steba Biotech said, and the company had submitted a marketing authorization application to the European Medicine Agency for authorization of Tookad as a treatment of localized prostate cancer.

The approved therapy was developed by Salomon and Scherz using a clever twist on photosynthesis called photodynamic therapy, in which elements are activated when they are exposed to a specific wavelength of light.

Tookad was first synthesized in Scherz’s lab from bacteriochlorophyll, the photosynthetic pigment of a type of aquatic bacteria that draw their energy supply from sunlight. Photosynthesis style, the infrared light activates Tookad (via thin optic fibers that are inserted into the cancerous prostatic tissue) which consists of oxygen and nitric oxide radicals that initiate occlusion and destruction of the tumor blood vessels.

These elements are toxic to the cancer cells and once the Tookad formula is activated, they invade the cancer cells, preventing them from absorbing oxygen and choking them until they are dead. The Tookad solution, having done its job, is supposed to then be ejected from the body, with no lingering consequences – and no more cancer.

With the drug approved for prostate cancer – and able to reach cancerous cells that are deep within the body via a minimally invasive procedure – Steba believes it may be able to treat other forms of cancer. In fact, the company said, it is also pursuing early stage studies of Tookad in esophageal cancer, urothelial carcinoma, advanced prostate cancer, renal carcinoma, and triple negative breast cancer in collaboration with Memorial Sloan Kettering Cancer Center, the Weizmann Institute, and Oxford University.

“The use of near-infrared illumination, together with the rapid clearance of the drug from the body and the unique non-thermal mechanism of action, makes it possible to safely treat large, deeply embedded cancerous tissue using a minimally invasive procedure,” according to Steba.

The Weizmann Institute has been working with Steba researchers for some 20 years to develop Tookad, said Amir Naiberg, CEO of the Yeda Research and Development Company, the Weizmann Institute’s technology transfer arm and the licensor of the therapy. “The commitment made by the shareholders of Steba and their personal relationship and effective collaboration with Weizmann Institute scientists and Yeda have enabled this tremendous accomplishment.”

“We are excited to bring a unique and innovative solution to physicians and patients for the management of low-risk prostate cancer in Mexico and subsequently to other Latin American countries,” said Raphael Harari, chief executive officer of Steba Biotech. “This approval is recognition of the tremendous effort deployed over the years by the scientists of Steba Biotech and the Weizmann Institute to develop a therapy that can control effectively low-risk prostate cancer while preserving patients’ quality of life.”

 

 

Original Study

http://www.timesofisrael.com/weizmann-developed-drug-cures-prostate-cancer-in-90-minutes-studies-show/?utm_source=Start-Up+Daily&utm_campaign=db10147d27-2016_04_04_SUI4_4_2016&utm_medium=email&utm_term=0_fb879fad58-db10147d27-54672313

Other articles on Prostate Cancer were published in this Open Access Online Scientific Journal, including the following:

Articles by Larry H. Bernstein

Nanoscale Photodynamic Therapy

https://pharmaceuticalintelligence.com/2016/02/05/nanoscale-photodynamic-therapy

Laser Therapy Opens Blood-Brain Barrier
https://pharmaceuticalintelligence.com/2016/03/17/laser-therapy-opens-blood-brain-barrier

Single Cell Shines Light on Cell Malignant Transformation  
https://pharmaceuticalintelligence.com/2016/01/29/single-cell-shines-light-on-cell-malignant-transformation

Low Energy Photon Intra-Operative Radiotherapy System
https://pharmaceuticalintelligence.com/2015/11/10/low-energy-photon-intra-operative-radiotherapy-system

Articles by the Team @PharmaceuticalIntelligence.com

Castration Resistant Prostate Cancer

University of Liverpool Scientists Report New Urine Test To Detect Potential Biomarkers of Prostate Cancer

Who and when should we screen for prostate cancer?

Reactive Oxygen species in prostate cancer?

Following (or not) the guidelines for use of imaging in management of prostate cancer

Controlling focused-treatment of Prostate cancer with MRI

Combining Nanotube Technology and Genetically Engineered Antibodies to Detect Prostate Cancer Biomarkers

In Search of Clarity on Prostate Cancer Screening, Post-Surgical Followup, and Prediction of Long Term Remission

Prostate Cancer Molecular Diagnostic Market – the Players are: SRI Int’l, Genomic Health w/Cleveland Clinic, Myriad Genetics w/UCSF, GenomeDx and BioTheranostics

Early Detection of Prostate Cancer: American Urological Association (AUA) Guideline

A Blood Test to Identify Aggressive Prostate Cancer: a Discovery @ SRI International, Menlo Park, CA

Prostate Cancer: Androgen-driven “Pathomechanism” in Early-onset Forms of the Disease

Prostate Cancer and Nanotecnology

Prostate Cancer Cells: Histone Deacetylase Inhibitors Induce Epithelial-to-Mesenchymal Transition

Imaging agent to detect Prostate cancer-now a reality

Scientists use natural agents for prostate cancer bone metastasis treatment

Today’s fundamental challenge in Prostate cancer screening

Prostate Cancers Plunged After USPSTF Guidance, Will It Happen Again?

Nanoparticle delivery to cancer drug targets

Perspectives on Anti-metastatic Effects in Cancer Research 2015

Identifying Cancers and Resistance

Peptides and anti-Cancer activity

Breakthrough work in cancer*

Imaging Technology in Cancer Surgery

Immunotherapy in Cancer: A Series of Twelve Articles in the Frontier of Oncology by Larry H Bernstein, MD, FCAP

Urological Cancers of Men

Current Advanced Research Topics in MRI-based Management of Cancer Patients

A Synthesis of the Beauty and Complexity of How We View Cancer

The importance of spatially-localized and quantified image interpretation in cancer management

Cancer Metastasis

Issues in Personalized Medicine in Cancer: Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

In Focus: Identity of Cancer Stem Cells

On the road to improve prostate biopsy

State of the art in oncologic imaging of Prostate.

New clinical results supports Imaging-guidance for targeted prostate biopsy

The Incentive for “Imaging based cancer patient’ management”

Topics in Pathology :Liquid Biopsy Assay May Predict Drug Resistance

Opening Ceremony and Award Presentations from the 2015 AACR Meeting in Philadelphia PA

Read Full Post »


Reporter: Aviva Lev-Ari, PhD, RN

The Hebrew University Leads in I-CORE Participation in Israel

 

Hebrew University faculty lead five I-CORE centers, and hold scientific management positions in five

Hebrew University leads a new generation of scientific and academic excellence. I-CORE – the Israeli Center for Research Excellence is a new initiative designed by the government of Israel to establish leading research centers specializing in crucial scientific and medical pursuits as well as studies of the humanities. I-CORE will strengthen Israel’s academic and research output in the long-term and sustain Israel’s stature worldwide.

 

The Israeli government has chosen The Hebrew University of Jerusalem to establish and lead five of the 16 Centers of Excellence in the innovative I-CORE program. Hebrew University faculty also hold scientific management positions in five additional I-CORE centers. The Technion, Weizmann Institute of Science, and Tel Aviv University each lead three centers, while the University of Haifa and Ben Gurion University each lead one.

 

Molecular Basis of Human Diseases

Director: Professor Howard Cedar, Molecular Biology, The Hebrew University.

Engage in the study of genetic regulation of common complex human diseases. By understanding these diseases better, this I-CORE hopes to find better approaches to prevent and treat them.

 

“Da’at Hamakom”: Center for the Study of Cultures of Place in the Modern Jewish World.

Director: Professor Richard Cohen, Jewish History and Contemporary Jewry, The Hebrew University.

This I-CORE seeks to address notions of Jewish identity, creativity, tradition, and forms of attachment and belonging in the modern era.

 

The Center for Empirical Studies of Decision Making and the Law

Director: Professor Ilana Ritov, School of Education, The Hebrew University

The I-CORE’s goals are to conduct studies that examine fundamental issues of the basic-science of law and decision-making, and to address important implications for concrete policy debates.

 

Astrophysics: from the Big Bang to Planets

Director: Professor Piran Tsvi, Racah Institute for Physics, The Hebrew University

 

The role of chromatin, RNA modifications and non-coding RNAs in regulation of gene expression in development and disease

Director: Professor Friedman Nir, School of Computer Science and Engineering, The Hebrew University

 

Israel Multidisciplinary Center for Mass Trauma Research: From Basic Research to Real Life Application

Scientific Management Member: Professor Hermona Soreq, Biological Chemistry, The Hebrew University

 

Center for the Study of Conversion and Inter-Religious Encounters

Scientific Management Member: Dr. Ram Ben-Shalom, Jewish History, The Hebrew University

 

The Quantum Universe

Scientific Management Member: Professor Rabinovici Eliezer, Racah Institute of Physics, The Hebrew University

The anticipated data from particle physics, gravity, cosmology, astrophysics and strings, is the basis of research of this center, and may well lead to major breakthroughs in the study of fundamental physics at all length scales.

 

Comprehensive understanding and modeling of plant responses to multiple abrupt abiotic stresses and to prolonged climatic changes

Scientific Management Member: Professor Weiss David, Robert H. Smith Institute for Plant Sciences and Genetics in Agriculture, The Hebrew University

The I-CORE will contribute to a more holistic view of a plant in a changing environment, will boost research of fundamental scientific questions, and will impact on the local Ag-Biotech industries towards improved plant robustness under changing climate.

Center of Excellence in Algorithms

Scientific Management Member: Professor Danny Dolev, School of Computer Science and Engineering, The Hebrew University

 http://hosted-p0.vresp.com/950643/a271d5cc16/ARCHIVE#like

The I-CORE Program in Israel

http://www.icoregroup.com/

The Israeli Centers for Research Excellence (I-CORE) is an initiative designed by the Planning and Budgeting Committee (PBC) and the Government of Israel. The initiative is part of the Higher Education multi-year Reform Plan, which gradually establishes leading research centers specializing in a range of disciplines. The Centers of Excellence and the program’s vision are aimed at fundamentally strengthening the long term positioning of Israel’s academic research and its stature among leading researchers in Israel and abroad.

 

I-CORE was endorsed by the Government of Israel and adopted by Israel’s Council of Higher Education in March 2010 (see The government decision here).

 

The program is jointly run by the PBC and the Israeli Science Foundation (ISF).

 

The I-CORE Steering Committee is in charge of designing and approving the program’s principles and modus operandi, the selection of research topics, the reviewing of the evaluation committees’ reports and declaration of the groups selected to establish the I-COREs.
The International Scientific Advisory Committee (SAC) of the program advises to the Steering Committee on the various issues, supplying it with an external professional perspective, and assists the ISF with managing the evaluation process.

The Program’s objectives are:

  • Strengthening scientific research in Israel and establishing Israel’s standing as a world leader in scientific research;
  • “Brain Return”: returning excellent researchers to Israel, as a central means of fortifying the research capabilities and the academic staffs of the institutions of higher education;
  • Creating a critical mass and intensifying the relative advantages in select fields in the different institutions;
  • Improving and upgrading the research infrastructure in the universities;
  • Encouraging academic innovation, including integration between different fields of knowledge (multi-disciplinarity);
  • Maintaining and promoting advanced programs of instruction and training in select fields;
  • Encouraging research collaboration between institutions of higher education, both universities and colleges;
  • Strengthening the scientific research in Israel in disciplines of system-wide and national importance
  • Promoting collaboration with leading researchers and research institutions worldwide.

 

A “Center of excellence” is an association of outstanding researchers in a specific research field, who are current staff members of different higher education institutions, for the purpose of promoting groundbreaking and innovative research. The center serves as an anchor for shared research infrastructure and research groups in this field, and allows optimal utilization of the scientific potential of Israel.

 

Apart from the research infrastructure that is being established and upgraded in the framework of the I-CORE, the members of the center benefit from a significant budget for the center’s activities, including international activities, scholarships for research students and postdoctoral fellows, usage of equipment and materials, technical HR etc.

 

In addition to the members of the I-CORE who are current staff members of Israeli institutions of higher education, new outstanding researchers also join the center during the first three years of activity. The new researchers join the various higher education institutions where they get a regular tenure-track academic appointment, and also receive annual research grants for a period of five years and equipment grants.

 

In order to encourage research collaborations between the various researchers in the center which come from various institutions, the program encourages joint mentoring of graduate students by researchers who are members of the center, regardless of their institutional affiliation. In addition, the program assists the I-CORE members in organizing workshops and unique programs of advanced teaching, including International Graduate programs, in developing partnerships with industry, and in contributing to the community by holding public lectures or programs for high school students.
The research topics selected for the Centers were selected in a wide bottom-up process of consultation with the Israeli academic community, such that they reflect the genuine priorities and scientific interest of researchers in Israel. Out of the large number of suggestions received by researchers, specific topics were chosen by designated committees. Once the topics were announced, a call for proposal was issued inviting groups of researchers to submit proposals for the establishment of I-COREs in these topics.
The evaluation and assessment processes of the proposals are carried out by the Israeli Science Foundation via international evaluation committees, which examine the proposals on a competitive basis. The evaluation and assessment processes are carried out in two stages – preliminary proposals and full proposals.
The first wave of I-COREs started operating in October 2011. 
The second wave 12 I-COREs, are expected to be established during 2013. The new Centers will span a wide array of topics in exact sciences, life sciences, engineering and medicine, as well as in social sciences, humanities, education and law.

 

Read Full Post »